

Amendments to the Claims:

This listing of the claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1-4 (Cancelled)

5 (Previously Presented). A vector comprising a DNA sequence according to claim 44.

6 (Original). A vector according to claim 5 capable of being expressed in a eukaryotic host cell

7 (Original). A vector according to claim 5 capable of being expressed in a prokaryotic host cell.

8 (Currently amended). A non-naturally occurring transformed eukaryotic or prokaryotic host ~~cells~~ cell containing a vector according to claim 5.

9-10 (Canceled)

11 (Previously Presented). A method for producing a polypeptide which potentiates cell death, which comprises growing a transformed host cell according to claim 55 under conditions suitable for the expression of an expression product, effecting post-translational modification of said expression product, as necessary, for obtaining said polypeptide, and isolating said expressed polypeptide.

12-22 (Canceled)

Appln. No. 09/445,223
Amdt. dated January 30, 2006
Reply to Office action of July 29, 2005

23 (Previously Presented). A composition comprising a pharmaceutically acceptable excipient and a recombinant animal virus vector comprising a DNA sequence according to claim 44.

24 (Currently Amended). A composition comprising a pharmaceutically acceptable excipient and an oligonucleotide molecule consisting of an antisense sequence of at least part of a DNA sequence encoding the polypeptide of SEQ ID NO:1, ~~said part of the DNA sequence being of sufficient length to~~ effectively antisense sequence being effective to block the expression of said polypeptide upon use.

25-43 (Canceled).

44 (Previously Presented). An isolated DNA sequence consisting essentially of a sequence encoding a polypeptide which potentiates cell death, said polypeptide consisting of:

(a) a sequence comprising SEQ ID NO:1;

(b) a sequence comprising an analog of (a) having no more than ten changes in the amino acid sequence of (a), each said change being a substitution, deletion or insertion of a single amino acid, which analog potentiates cell death;
or

(c) a fragment of the sequence of SEQ ID NO:1, which fragment potentiates cell death.

45 (Previously Presented). A DNA sequence in accordance with claim 44 consisting essentially of a sequence encoding a polypeptide of a sequence comprising SEQ ID NO:1.

46 (Previously Presented). A DNA sequence in accordance with claim 44, consisting essentially of a sequence encoding a polypeptide consisting of the sequence of (b).

47 (Previously Presented). A DNA sequence in accordance with claim 44, consisting essentially of a sequence encoding a polypeptide consisting of the sequence of (c).

48 (Previously Presented). A DNA sequence in accordance with claim 44, consisting essentially of SEQ ID NO:2 or a portion thereof encoding a polypeptide which potentiates cell death.

49-50 (Canceled).

51 (Currently Amended). An isolated oligonucleotide molecule consisting of an antisense sequence of at least a part of a DNA sequence encoding the polypeptide of SEQ ID NO:1, ~~said part of the DNA sequence being of sufficient length to effectively~~ antisense sequence being effective to block the expression of said polypeptide upon use.

52-53 (Cancelled)

54 (Previously Presented). An isolated DNA sequence in accordance with claim 44 wherein the entire DNA sequence is a coding sequence encoding said polypeptide.

55 (Currently Amended). ~~Isolated~~ An isolated transformed eukaryotic or prokaryotic host ~~cells~~ cell containing a vector according to claim 5.

56 (Currently Amended). A composition comprising a pharmaceutically acceptable excipient and an oligonucleotide molecule consisting of an antisense sequence of at least part of a mRNA sequence encoding the polypeptide of SEQ ID NO:1, ~~said part of the mRNA sequence being of sufficient length to~~ effectively antisense sequence being effective to block the expression of said polypeptide upon use.

57 (Currently amended). An isolated oligonucleotide molecule consisting of an antisense sequence of at least a part of a mRNA sequence encoding the polypeptide of SEQ ID NO:1, ~~said part of the mRNA sequence being of sufficient length to effectively~~ antisense sequence being effective to block the expression of said polypeptide upon use.